Phase I/II Study of Venetoclax in Combination With Ublituximab and Umbralisib (TGR-1202) in Patients With Relapsed or Refractory CLL/SLL
Phase of Trial: Phase I/II
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs Ublituximab (Primary) ; Umbralisib (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Sponsors TG Therapeutics Inc
- 06 Nov 2019 According to a TG Therapeutics media release, data for the triple combination of U2 (umbralisib and ublituximab) plus venetoclax has been accepted for oral presentation at the upcoming 61st American Society of Hematology (ASH) annual meeting and exposition (7th to 10th Dec 2019), at the Orange County Convention Center in Orlando, FL.
- 06 Nov 2019 Preliminary results presented in a TG Therapeutics media release.
- 30 Apr 2018 Planned End Date changed from 1 Aug 2020 to 1 Dec 2021.